Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 348124, 8 pages
http://dx.doi.org/10.1155/2015/348124
Clinical Study

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

1Department of Medical Oncology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands
2Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands
3Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands
4Department of Endocrinology, University Medical Center Groningen, 9700 RB Groningen, Netherlands
5Department of Clinical Pharmacy, Radboud University Nijmegen Medical Center, 6525 GA Nijmegen, Netherlands

Received 5 November 2014; Accepted 17 June 2015

Academic Editor: Constantinos Pantos

Copyright © 2015 T. C. Schneider et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Results of somatic mutation hotspot analysis. One MEN2A patient carried a germline RET c.1858T>C, p.Cys620Arg mutation. Four tumors showed a somatic RET c.2753T>C, p.Met918Thr mutation, including one that also carried an EGFR c.2543C>T, p.Pro848Leu mutation.

  1. Supplementary Material